Zelrix: Additional Phase III data

Updated data from a double-blind Phase III trial in 530 acute migraine patients showed that Zelrix met the primary endpoint of a significantly greater proportion of patients who were pain free at 2 hours vs. placebo patch (18% vs. 9%, p<0.0001). Zelrix also met the secondary endpoints of a significantly greater proportion of patients vs. placebo patch who were nausea free (84% vs. 63%, p<0.0001), photophobia free (51% vs. 36%, p=0.0028), phonophobia free (55% vs. 39%, p=0.0002) and a greater proportion of patients who experienced pain relief (53% vs. 29%, p<0.0001) at 2 hours. The company previously reported that Zelrix met the endpoints (see BioCentury, Aug. 17). ...